{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:35:19Z","timestamp":1790649319220,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012816","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T00:00:00Z","timestamp":1539561600000}}],"reference-count":66,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012816.pub2","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T09:51:22Z","timestamp":1539597082000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer"],"prefix":"10.1002","volume":"2018","author":[{"given":"Niranjan J","family":"Sathianathen","sequence":"first","affiliation":[{"name":"University of Minnesota; Department of Urology; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiannis A","family":"Philippou","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Surgical Sciences; John Radcliffe Hospital Headington Oxford UK OX39DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen M","family":"Kuntz","sequence":"additional","affiliation":[{"name":"University of Florida-Jacksonville; Borland Health Sciences Library; 653-1 West Eight St. 2nd FL LRC Jacksonville Florida USA 32209"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Badrinath R","family":"Konety","sequence":"additional","affiliation":[{"name":"University of Minnesota; Department of Urology; Minneapolis Minnesota USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shilpa","family":"Gupta","sequence":"additional","affiliation":[{"name":"University of Minnesota; Department of Medicine, Division of Hematology, Oncology and Transplatation; Minneapolis USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alastair D","family":"Lamb","sequence":"additional","affiliation":[{"name":"University of Oxford; Nuffield Department of Surgical Sciences; John Radcliffe Hospital Headington Oxford UK OX39DU"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Dahm","sequence":"additional","affiliation":[{"name":"University of Minnesota; Department of Urology; Minneapolis Minnesota USA"},{"name":"Minneapolis VA Health Care System; Urology Section; One Veterans Drive Mail Code 112D Minneapolis Minnesota USA 55417"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,10,15]]},"reference":[{"key":"10.1002\/14651858.CD012816.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized Phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.07.008","article-title":"Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial","volume":"84","author":"Marino","year":"2017","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD012816.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2017.75.3921","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"Journal of Clinical Oncology"},{"issue":"6 Supplement","key":"10.1002\/14651858.CD012816.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1200\/JCO.2017.35.6_suppl.137","article-title":"Lower PSA at 7 months is prognostic for improved overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC) treated with ADT with and without docetaxel (D)","volume":"35","author":"Harshman","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Kyriakopoulos CE Chen Y-H Carducci MA Liu G Jarrard DF Hahn NM Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival Analysis of the randomized phase III E3805 CHAARTED Trial Journal of Clinical Oncology 2018 1080 7","DOI":"10.1200\/JCO.2017.75.3657"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0008|cit8","doi-asserted-by":"crossref","unstructured":"Morgans AK Chen Y-H Sweeney CJ Jarrard DF Plimack ER Gartrell BA Quality of life during treatment with chemohormonal therapy: analysis of E3805 chemohormonal androgen ablation randomized trial in prostate cancer Journal of Clinical Oncology 2018 1088 95","DOI":"10.1200\/JCO.2017.75.3335"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"5004","DOI":"10.1200\/JCO.2016.34.15_suppl.5004","article-title":"Quality of life (QOL) analysis from CHAARTED: chemohormonal androgen ablation randomized trial in prostate cancer (E3805)","volume":"34 Suppl 15","author":"Patrick-Miller","year":"2016","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0010|cit10","first-page":"720","article-title":"Long term efficacy and QOL data of chemohormonal therapy (C-HT) in low and high volume hormone na\u00efve metastatic prostate cancer (PrCa): E3805 CHAARTED trial","volume":"27(Supplement 6","author":"Sweeney","year":"2016","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1200\/JCO.2017.35.6_suppl.259","article-title":"An update on clinical outcome data for a phase II randomized study comparing androgen deprivation therapy plus docetaxel versus androgen deprivation therapy alone in men with locally advanced\/metastatic hormone sensitive prostate cancer","volume":"35 Suppl 6","author":"Hassani","year":"2017","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"Berruti A Tucci M Mosca A Tarabuzzi R Gorzegno G Terrone C Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease British Journal of Cancer 2005 633 6","DOI":"10.1038\/sj.bjc.6602767"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1371\/journal.pone.0157660","article-title":"Efficacy and safety of combined androgen deprivation therapy (ADT) and docetaxel compared with ADT alone for metastatic hormone-naive prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Botrel","year":"2016","journal-title":"PloS One"},{"issue":"1","key":"10.1002\/14651858.CD012816.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1524-4733.2008.00409.x","article-title":"Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy - Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer","volume":"12","author":"Cella","year":"2009","journal-title":"Value Health"},{"issue":"4","key":"10.1002\/14651858.CD012816.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","article-title":"EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer","volume":"71","author":"Cornford","year":"2017","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0017|cit17","unstructured":"Veritas Health Innovation Covidence"},{"issue":"18","key":"10.1002\/14651858.CD012816.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"6019","DOI":"10.1158\/0008-5472.CAN-11-1417","article-title":"Taxane-Induced Blockade to Nuclear Accumulation of the Androgen Receptor Predicts Clinical Responses in Metastatic Prostate Cancer","volume":"71","author":"Darshan","year":"2011","journal-title":"Cancer Research"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0019|cit19","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0020|cit20","doi-asserted-by":"crossref","unstructured":"Engels FK Sparreboom A Mathot RAA Verweij J Potential for improvement of docetaxel-based chemotherapy: a pharmacological review British Journal of Cancer 2005 173 7","DOI":"10.1038\/sj.bjc.6602698"},{"issue":"4","key":"10.1002\/14651858.CD012816.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"21","key":"10.1002\/14651858.CD012816.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"8386","DOI":"10.1158\/0008-5472.CAN-09-1504","article-title":"Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer","volume":"69","author":"Gan","year":"2009","journal-title":"Cancer Research"},{"issue":"8","key":"10.1002\/14651858.CD012816.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/annonc\/mdv257","article-title":"Management of patients with advance prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015","volume":"26","author":"Gillessen","year":"2015","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0024|cit24","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"6","key":"10.1002\/14651858.CD012816.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"European Urology"},{"issue":"7651","key":"10.1002\/14651858.CD012816.pub2-BIB0026|cit26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD012816.pub2-BIB0027|cit27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction - GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Hamdy FC Donovan JL Lane JA Mason M Metcalfe C Holding P 10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer New England Journal of Medicine 2016 1415 24","DOI":"10.1056\/NEJMoa1606220"},{"issue":"11","key":"10.1002\/14651858.CD012816.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD012816.pub2-BIB0030|cit30","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0031|cit31","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0032|cit32","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0033|cit33","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0034|cit34","doi-asserted-by":"crossref","unstructured":"Huggins C Stevens RE Jr Hodges CV Studies on prostatic cancer: II. the effects of castration on advanced carcinoma of the prostate gland Archives of Surgery 1941 209 23","DOI":"10.1001\/archsurg.1941.01210140043004"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0035|cit35","doi-asserted-by":"crossref","unstructured":"Inoue T Segawa T Kamba T Yoshimura K Nakamura E Nishiyama H Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan Urology 2009 1104 9","DOI":"10.1016\/j.urology.2008.07.062"},{"issue":"6","key":"10.1002\/14651858.CD012816.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.eururo.2014.09.032","article-title":"Survival with newly diagnosed metastatic prostate cancer in the \"docetaxel era\": data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK\/06\/019)","volume":"67","author":"James","year":"2015","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD012816.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012816.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0090-4295(96)00496-7","article-title":"Combined hormone\/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group","volume":"49","author":"Janknegt","year":"1997","journal-title":"Urology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0039|cit39","unstructured":"Jordan MA Wendell K Gardiner S Derry WB Copp H Wilson L Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death Cancer Research 1996 816 25"},{"issue":"2","key":"10.1002\/14651858.CD012816.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0041|cit41","doi-asserted-by":"crossref","unstructured":"Kirby M Hirst C Crawford ED Characterising the castration-resistant prostate cancer population: a systematic review International Journal of Clinical Practice 2011 1180 92","DOI":"10.1111\/j.1742-1241.2011.02799.x"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Kyriakopoulos CE Chen Y-H Carducci MA Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized Phase III E3805 CHAARTED Trial Journal of Clinical Oncology 2018 1080 7","DOI":"10.1200\/JCO.2017.75.3657"},{"issue":"7","key":"10.1002\/14651858.CD012816.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0044|cit44","doi-asserted-by":"crossref","unstructured":"Loos WJ Baker SD Verweij J Boonstra JG Sparrebom A Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins Clinical Pharmacology and Therapeutics 2003 364 71","DOI":"10.1016\/S0009-9236(03)00222-4"},{"issue":"36","key":"10.1002\/14651858.CD012816.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1200\/JCO.2007.15.9830","article-title":"Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer","volume":"26","author":"Millikan","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0046|cit46","unstructured":"Mohler JL Armstrong AJ Bahnson RR D'Amico AV Davis BJ Eastham JA NCCN clinical practice guidelines in oncology: prostate cancer National Comprehensive Cancer Network 2017"},{"issue":"7","key":"10.1002\/14651858.CD012816.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-U","article-title":"Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone","volume":"51","author":"Murphy","year":"1983","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"v69","DOI":"10.1093\/annonc\/mdv222","article-title":"Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26 Suppl 5","author":"Parker","year":"2015","journal-title":"Annals of Oncology"},{"issue":"24","key":"10.1002\/14651858.CD012816.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0050|cit50","doi-asserted-by":"crossref","unstructured":"Petrylak DP Tangen CM Hussain MHA Lara PN Jones JA Taplin ME Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer New England Journal of Medicine 2004 1513 20","DOI":"10.1056\/NEJMoa041318"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0051|cit51","first-page":"81","article-title":"Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer","volume":"32 Suppl 3","author":"Pummer","year":"1997","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0052|cit52","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5) 2014"},{"issue":"1","key":"10.1002\/14651858.CD012816.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/pcan.2016.62","article-title":"Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials","volume":"20","author":"Saad","year":"2017","journal-title":"Prostate Cancer Prostatic DIs"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0054|cit54","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD012816.pub2-BIB0055|cit55","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0056|cit56","unstructured":"Taguchi T Furue H Niitani H Ishitani K Kanamaru R Hasegawa K Phase I clinical trial of RP 56976 (docetaxel) a new anticancer drug Gan To Kagaku Ryoho 1994 1997 2005"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0057|cit57","doi-asserted-by":"crossref","unstructured":"Tannock IF de Wit R Berry WR Horti J Pluzanska A Chi KN Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer New England Journal of Medicine 2004 1502 12","DOI":"10.1056\/NEJMoa040720"},{"issue":"12","key":"10.1002\/14651858.CD012816.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1093\/annonc\/mdt397","article-title":"Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials","volume":"24","author":"Templeton","year":"2013","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0060|cit60","doi-asserted-by":"crossref","unstructured":"Tilki D Schaeffer EM Evans CP Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor European Urology Focus 2016 499 505","DOI":"10.1016\/j.euf.2016.11.013"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0061|cit61","first-page":"87","article-title":"Global cancer statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA: a Cancer Journal for Clinicians"},{"issue":"3","key":"10.1002\/14651858.CD012816.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Seminars in Radiation Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"Tucci M Bertaglia V Vignani F Buttigliero C Fiori C Porpiglia F Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis European Urology 2016 563 73","DOI":"10.1016\/j.eururo.2015.09.013"},{"issue":"2","key":"10.1002\/14651858.CD012816.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncology"},{"key":"10.1002\/14651858.CD012816.pub2-BIB0065|cit65","doi-asserted-by":"crossref","unstructured":"Zhu ML Horbinski C Garzotto M Qian DZ Beer TM Kyprianou N Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer Cancer Research 2010 7992 8002","DOI":"10.1158\/0008-5472.CAN-10-0585"},{"issue":"9","key":"10.1002\/14651858.CD012816.pub2-BIB0066|cit66","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012816","article-title":"Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer","author":"Sathianathen","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012816.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T07:17:29Z","timestamp":1656919049000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012816.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,10,15]]},"references-count":66,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2018,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012816.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,15]]}}}